Vaxcyte, Inc.
Financials
Valuation Metrics
Vaxcyte, Inc.'s Market Cap is $8.98B. At end of 2025 it was $6.28B. Ranked #996 of 3,121 in US market (top 32%), #319 of 1,463 on NASDAQ (top 22%), #50 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.98B | US#996/3,121 Sec#50/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-1.06B | US—/3,121 Sec—/266 |
| Total Assets | $3.14B | US#1,789/3,121 Sec#46/266 |
| Net Assets | $2.76B | US#1,032/3,121 Sec#35/266 |
| Employees | 507 | US#2,275/3,121 Sec#83/266 |
| Value | ||
| P/B | 3.26x | US#1,844/3,121 Sec#95/266 |
| FCF Yield | -13.39% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -38.59% | US#2,620/3,121 Sec#133/266 |
| ROA | -33.91% | US#2,911/3,121 Sec#166/266 |
| Financial Health | ||
| Debt Ratio | 13.79% | US#157/3,121 Sec#65/266 |
| Total Debt | $115M | US#2,402/3,121 Sec#110/266 |
| FCF | $-1.20B | US#2,970/3,121 Sec#260/266 |
| Cash | $183M | US#1,805/3,121 Sec#116/266 |
| Current Ratio | 5.72x | US#412/3,121 Sec#129/266 |
| Performance | ||
| 1Y Return | 95.44% | US#239/3,121 Sec#67/266 |
| 1M Return | 0.97% | US#829/3,121 Sec#82/266 |
| From 52W High | -7.12% | US#497/3,121 Sec#34/266 |
| 1Y MDD | -27.95% | US#1,274/3,121 Sec#78/266 |
| Trading | ||
| Volume | 1,272,391 shares | US#1,192/3,121 Sec#120/266 |
| Trading Value | $77M | US#987/3,121 Sec#70/266 |
| Per Share | ||
| EPS | $-7.15 | US—/3,121 Sec—/266 |
| BPS | $18.53 | US#1,315/3,121 Sec#32/266 |
Company Info
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.